439O - A first in human, phase I trial of NP137, a first-in-class antibody targeting netrin-1, in patients with advanced refractory solid tumors. - Cassier, P.; Eberst, L.; Garin, G.; Courbebaisse, Y.; Terret, C.; Robert, M.; Frenel, J.-S.; Depil, S.; Delord, J.-P.; Perol, D.; Ray-Coquard, I.L.; Bidaux, A.-S.; et al. (Annals of Oncology, 2019)